Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments

Lina Quteineh, Frederik Vandenberghe, Nuria Saigi Morgui, Aurélie Delacrétaz, Eva Choong, Mehdi Gholam-Rezaee, Pierre J. Magistretti, Guido Bondolfi, Armin Von Gunten, Martin A. Preisig, Enrique Castelao, Peter Vollenweider, Gérard Waeber, Murielle Bochud, Zoltán Kutalik, Philippe O. Conus, Chin Bin Eap

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Background Metabolic syndrome (MetS) associated with psychiatric disorders and psychotropic treatments represents a major health issue. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme that catalyzes tissue regeneration of active cortisol from cortisone. Elevated enzymatic activity of 11β-HSD1 may lead to the development of MetS. Methods We investigated the association between seven HSD11B1 gene (encoding 11β-HSD1) polymorphisms and BMI and MetS components in a psychiatric sample treated with potential weight gain-inducing psychotropic drugs (n=478). The polymorphisms that survived Bonferroni correction were analyzed in two independent psychiatric samples (n R1 =168, n R2 =188) and in several large population-based samples (n 1 =5338; n 2 =123 865; n 3 >100 000). Results HSD11B1 rs846910-A, rs375319-A, and rs4844488-G allele carriers were found to be associated with lower BMI, waist circumference, and diastolic blood pressure compared with the reference genotype (P corrected
Original languageEnglish (US)
Pages (from-to)246-258
Number of pages13
JournalPharmacogenetics and Genomics
Volume25
Issue number5
DOIs
StatePublished - Mar 9 2015

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Molecular Biology
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments'. Together they form a unique fingerprint.

Cite this